FIELD: medical equipment.
SUBSTANCE: group of inventions refers to means for direct introduction of a dose of an antitumour preparation calculated in accordance with a patient's parameter. What is presented is a perfusion system which enables hospitals or clinics to administer directly to a patient in need thereof an antitumour preparation, calculated in accordance with the parameter of the patient, where such a parameter varies within a certain range among the patients. Said system comprises: a plurality of perfusion containers, each containing an anti-tumor preparation ready for infusion, where said plurality of perfusion containers comprises a first set of one or more perfusion containers containing an aqueous infusion solution of an antitumour preparation ready for infusion, and a second set of additional perfusion containers containing an aqueous infusion solution of an antitumour preparation ready for infusion, as well as (optionally) a third set of additional perfusion containers, containing an infusion-ready aqueous perfusion solution of an antitumour agent. In addition, the system comprises indications for selecting one or more perfusion containers from the first set and, if necessary, one or more additional perfusion containers from the second and/or third sets for direct introduction of the calculated dose of the antitumour preparation from the selected perfusion containers. A method and a perfusion container for direct administration to a patient of a dose of an antitumour preparation calculated in accordance with a patient's parameter are also described.
EFFECT: higher accuracy, reliability and safety of introduction.
29 cl, 81 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL FORM OF GEMCITABINE OF LARGE VOLUME FOR INFUSION AND KIT CONTAINING FORMULATIONS | 2013 |
|
RU2621144C2 |
TREATMENT OF STOMACH CANCER USING COMBINATION TYPES OF THERAPY CONTAINING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUOROURACIL (AND LEUCOVORIN) | 2017 |
|
RU2761953C2 |
METHODS OF TREATING PANCREAS CANCER USING COMBINATION THERAPY INCLUDING LIPOSOMAL IRINOTECAN | 2013 |
|
RU2808427C2 |
METHOD OF MALIGNANT TUMOR CHEMOTHERAPY | 1991 |
|
RU2012337C1 |
METHOD OF TREATING RECURRENT NASOPHARYNX CANCER | 2009 |
|
RU2420333C2 |
METHOD OF TREATING INOPERABLE PANCREATIC HEAD ADENOCARCINOMA | 2019 |
|
RU2706341C1 |
THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPY COMPRISING LIPOSOMAL IRINOTECAN | 2013 |
|
RU2663450C2 |
METHOD OF TREATING OPERABLE PANCREATIC HEAD ADENOCARCINOMA | 2019 |
|
RU2706347C1 |
METHOD OF TREATING OPERABLE PANCREATIC HEAD ADENOCARCINOMA | 2019 |
|
RU2706339C1 |
Authors
Dates
2020-07-31—Published
2017-02-09—Filed